Manuscript no. HAEMATOI/2009/019182 entitled "VALUE OF ALLOGENEIC STEM CELL TRANSPLANTATION (SCT) VERSUS AUTOLOGOUS SCT AND CHEMOTHERAPY IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND SECONDARY ACUTE MYELOID LEUKEMIA" Authors: Theo de Witte, Anne Hagemeijer, Stefan Suciu, Amin Belhabri, Michel Delforge, Guido Kobbe, Dominik Selleslag, Harry C. Schouten, Augustin Ferrant, Harald Biersack, Sergio Amadori, Petra Muus, Joop H. Jansen Eva Hellström-Lindberg, Tibor Kovacsovics, Pierre Wijermans, Gert Ossenkoppele, Alois Gratwohl, Jean-Pierre Marie, Roel Willemze

Information about the contributions of each person named as having participated in the study

- 1) Guarantor(s), i.e., person(s) who is (are) responsible for the integrity of the work as a whole:
- De Witte, Radboud University Medical Centre Nijmegen, Nijmegen, Netherlands; t.dewitte@ncmls. ru.nl
- Suciu Stefan, EORTC Headquarters, Brussels, Belgium, stefan.suciu@eortc.be

According to the International Committee of Medical Journal Editors (ICMJE) (http://www.icmje.org/ethical_1author.html): "Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3 Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship".

The guarantors of this manuscript confirm that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

- 2) Authors who participated in the conception of the study: Theo de Witte, Anne Hagemeijer, Stefan Suciu, Amin Belhabri, Michel Delforge, Guido Kobbe, Dominik Selleslag, Harry C. Schouten, Augustin Ferrant, Harald Biersack, Sergio Amadori, Petra Muus, Joop H. Jansen Eva Hellström-Lindberg, Tibor Kovacsovics, Pierre Wijermans, Gert Ossenkoppele, Alois Gratwohl, Jean-Pierre Marie, Roel Willemze
- 3) **Design & Methods**. The following authors were responsible for specific investigations:
- ,Anne Hagemeijer was responsible for for cytogenetic and FISH analyses and interpretation
- Joop Jansen was responsible for the molecular analyses and interpretation
- 4) **Results**. The following authors were responsible for specific portions of the results, including figures and tables (please indicate the person responsible for each figure and each table):
- Stefan Suciu was responsible for the statistical analyses and the design of the figures 2-4
- Theo de Witte was responsible for the design of the tables and figure 1
- 5) Writing the manuscript. The following authors were responsible for writing the manuscript:

- Theo de Witte, and Stefan Suciu were responsible for writing the manuscript
- Theo de Witte, Anne Hagemeijer, Stefan Suciu, Amin Belhabri, Michel Delforge, Guido Kobbe, Dominik Selleslag, Harry C. Schouten, Augustin Ferrant, Harald Biersack, Sergio Amadori, Petra Muus, Joop H. Jansen⁻ Eva Hellström-Lindberg, Tibor Kovacsovics, Pierre Wijermans, Gert Ossenkoppele, Alois Gratwohl, Jean-Pierre Marie, Roel Willemze were responsible for the final version of the manuscript.
- 6) Contributors Listed in Acknowledgments: (Examples of those who might be acknowledged include a person who provided purely technical help, writing assistance, or a department chair who provided only general support. Corresponding authors must declare whether they had assistance with the study design, data collection, data analysis, or manuscript preparation. If such assistance was available, the authors must disclose the identity of the individuals who provided this assistance and the entity that supported it. Financial and material support should also be acknowledged.)

The following investigators participated to this study:

Institution	Name/Centre (Country)
101	Pr. Bron, Institut J. Bordet, Brussels (BE)
109	Dr. Selleslag, A.Z. St Jan, Bruges (BE)
114	Dr. De Bock, A.Z. Middelheim, Antwerpen (BE)
117	Pr. Berneman, U.Z. Antwerpen, Antwerpen (BE)
121	Pr. Ferrant, Clin. Univ. St. Luc, Brussels (BE)
123	Dr. Bosly, C.U. De Mont Godinne, Yvoir (BE)
131	Pr. Feremans, University Hospital Erasme, Brussels (BE)
147	Drs. Delforge, U.Z. Gasthuisberg, Leuven (BE)
218	Pr. Thyss, Centre A. Lacassagne, Nice (FR)
242	Drs. Michallet, Thomas, Belhabri, Hopital E.Herriot, Lyon (FR)
245	Pr. Marie, Hotel-Dieu, Paris (FR)
269	Pr. Varet, H. Necker, Paris (FR)
302	Pr. Lowenberg, U.Z. Rotterdam (NL)
304	Pr. De Witte, Dr. Muus, University Medical Centre Nijmegen, Nijmegen (NL)
308	Dr. Ossenkoppele, VU Medical Centrum Amsterdam (NL)

Acknowledgements of research support

This study was supported by Kankerbestrijding/Koningin Wilhelmina Fonds, The Netherlands, Biomed-2 EU grant PL 95-0357, Fonds Cancer (FOCA) from Belgium, and also by grants from the US National Cancer Institute (grant numbers 5U10 CA11488-26 through 5U10 CA11488-38). Its

contents are solely the responsibility of the authors and do not represent the official views of the National Cancer Institute (Bethesda, Maryland, USA). Pharmacia-Upjohn provided an educational grant.